U.S. markets closed

Integra Launches AmnioExcel Placental Allograft Membrane

Zacks Equity Research

Integra LifeSciences IART recently launched the AmnioExcel Plus Placental Allograft Membrane. This product, launched under the company’ wound care portfolio, is designed to aid the repair of soft tissue.

The launch is expected to boost the company’s Orthopedics and Tissue Technologies (“OTT”) segment.

More About the Product

AmnioExcel Plus is a next generation, thicker, tri-layer, non-side specific allograft constituting of amnion-chorion-amnion layers that enables the process of complex wound closure. The proprietary DryFlex processing technology conserves the characteristic growth factors, cytokines and extracellular matrix found in native placental tissue. The room temperature storage, the five-year durability and convenience of use make it a superior product.

AmnioExcel Plus is a novel technology utilized by physicians in both the operating room and outpatient wound care setting, and is equipped to cater to around 8.2 million wounds with an estimated cost to Medicare of up to $98.6 billion annually.

 

Market Prospects

Per Markets and Markets, the global wound care market is expected to reach $24.8 billion by 2024 from $19.8 billion in 2019, at a CAGR of 4.6%. Hence, this product launch comes at an ideal time.

Recent Developments

In the fourth quarter of 2019, the company’s OTT segment registered 1.3% growth year over year. Organically, the segment grew 1.6% owing to a sales uptick in wound reconstruction. Wound reconstruction revenues, in turn, rose on the company’s robust performance in inpatient, plastics and reconstructive portfolios.

Price Performance

Shares of Integra have dropped 5.8% in the past year compared with the industry’s 1.3% rise.

Zacks Rank & Key Picks

Currently, Integra carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are ResMed Inc. RMD, Medtronic plc MDT and Hill-Rom Holdings, Inc. HRC.

ResMed has a projected long-term earnings growth rate of 12%. It currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Medtronic’s long-term earnings growth rate is estimated at 7.4%. The company presently carries a Zacks Rank #2 (Buy).

Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank #2.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Medtronic PLC (MDT) : Free Stock Analysis Report
 
Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
Hill-Rom Holdings, Inc. (HRC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.